Amphastar Pharmaceuticals (NASDAQ:AMPH) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research note issued to investors on Friday, Marketbeat.com reports. The brokerage issued an equal weight rating and a $55.00 price target on the stock.

A number of other equities research analysts have also issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler cut their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $60.33.

Amphastar Pharmaceuticals Trading Up 2.0 %

Shares of AMPH opened at $45.46 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The company’s fifty day moving average is $48.26 and its 200 day moving average is $44.45. The stock has a market capitalization of $2.19 billion, a PE ratio of 15.15, a P/E/G ratio of 0.89 and a beta of 0.82.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total transaction of $139,410.00. Following the sale, the director now owns 75,409 shares of the company’s stock, valued at $3,504,256.23. The trade was a 3.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Yakob Liawatidewi sold 5,214 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the sale, the executive vice president now directly owns 74,938 shares of the company’s stock, valued at $3,900,522.90. The trade was a 6.51 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,533 shares of company stock worth $1,378,252. 27.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC lifted its stake in Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after purchasing an additional 273 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. increased its holdings in shares of Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock valued at $56,000 after purchasing an additional 398 shares during the last quarter. Innealta Capital LLC purchased a new position in Amphastar Pharmaceuticals during the second quarter worth approximately $55,000. Blue Trust Inc. grew its holdings in Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after buying an additional 309 shares in the last quarter. Finally, Asset Management One Co. Ltd. acquired a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter worth $78,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.